Reports Q2 revenue $37,000 vs $154,000 last year. “We maintain a strong operational momentum as we track towards further potential value catalysts, most importantly presentation of the two-year EVX-01 clinical data and potential exercise by MSD of one or two of their options on EVX-B2 and EVX-B3. Business development discussions remain a key priority, both in terms of advancing ongoing discussions and entering new ones, as we pursue the remaining company milestones set for 2025,” says Birgitte Rono, CSO and interim CEO of Evaxion.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on EVAX:
- Evaxion A/S to Present Q2 2025 Financial Results and Business Update
- Evaxion to Present Promising Phase 2 Results of Cancer Vaccine at ESMO 2025
- Evaxion to present two-year clinical efficacy data from Phase 2 EVX-01 trial
- Evaxion Biotech Finalizes Debt Settlement with EIB
- Evaxion Converts Debt to Equity in EIB Agreement